ロード中...
Adalimumab for maintenance of remission in Crohn's disease
BACKGROUND: Conventional medications for Crohn's disease (CD) include anti‐inflammatory drugs, immunosuppressants and corticosteroids. If an individual does not respond, or loses response to first‐line treatments, then biologic therapies such as tumour necrosis factor‐alpha (TNF‐α) antagonists...
保存先:
| 出版年: | Cochrane Database Syst Rev |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Ltd
2020
|
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7386457/ https://ncbi.nlm.nih.gov/pubmed/32413933 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012877.pub2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|